Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: L. invasa populations sequencing

PROVIDER: PRJNA637475 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11935563_1.fastq.gz	Fastqsanger.gz
	SRR11935563_2.fastq.gz	Fastqsanger.gz
	SRR11935564_1.fastq.gz	Fastqsanger.gz
	SRR11935564_2.fastq.gz	Fastqsanger.gz
	SRR11935565_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Project description:L. invasa sequencing

| PRJNA549559 | ENA

Leptocybe invasa

Project description:Leptocybe invasa Genome sequencing

| PRJNA737053 | ENA

Leptocybe invasa

Project description:Leptocybe invasa Raw sequence reads

| PRJNA806504 | ENA

Leptocybe invasa

Project description:Sequencing of bacterial 16S rRNA sequence between Leptocybe invasa lineages

| PRJNA845099 | ENA

Soil Metaproteomics LC-MS

Project description:Sensitive models of climate change impacts would require a better integration of multi-omics approaches that connect the abundance and activity of microbial populations. Here, we show that climate is a fundamental driver of the protein abundance of microbial populations (metaproteomics), yet not their genomic abundance (16S rRNA gene amplicon sequencing), supporting the hypothesis that metabolic activity may be more closely linked to climate than community composition.

2022-03-01 | PXD009773 | Pride

Project description:Fungal communities of Eucalyptus grandis leaves infected by Leptocybe invasa

| PRJNA791551 | ENA

Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study

Project description:COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients. For each phase II trial, patient will be randomized between two arms with two patients randomized in arm A for one patient randomized in arm B: * Arm A (Experimental - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis) * Arm B (Standard - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging).

| 2329230 | ecrin-mdr-crc

Long non-coding RNAs in B cells (ChIP-Seq)

Project description:Using RNA sequencing and de novo transcript assembly, we identified 4516 lncRNAs expressed in 8 different stages of B cell development and activation. Chromatin immuno-precipitation sequencing was used to classify a substantial fraction (38%) of these lncRNAs as enhancer-associated or promoter-associated RNAs (eRNAs or pRNAs). A catalogue of lncRNAs expressed in eight murine B cell populations

2016-07-15 | E-GEOD-72017 | biostudies-arrayexpress

Whole-genome resequencing of BC1 populations from Arabidopsis (Col x Ler) x Col crosses (wild type)

Project description:This experiment aims at analyzing crossover distribution in male and female meiosis, in the Arabidopsis. Wild-type Col plant was crossed with Ler plant to produce F1 hybrid. Then, the F1 hybrid was crossed as female or as male with wild-type Col to generate two BC1 populations. Leaf samples from plants of the obtained BC1 populations were used for DNA purification and library preparation for Illumina sequencing (HiSeq 3000 2x150 bp), performed by the Max Planck-Genome-centre Cologne, Germany (https://mpgc.mpipz.mpg.de/home/) and Novogene.

2022-06-14 | E-MTAB-11254 | biostudies-arrayexpress

Cancer Health Assessments Reaching Many

Project description:The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at risk for hereditary cancer syndromes. The primary objective is to implement a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators will assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators will also assess the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.

| 2265388 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data